EFFICACY AND SAFETY OF GEMCITABINE AS FIRST-LINE THERAPY IN PATIENTS AGED 65 AND OLDER WITH ADVANCED PANCREATIC CANCER

被引：0
|
作者：
Kito, Yosuke [1 ]
Todaka, Akiko [1 ]
Fukutomi, Akira [1 ]
Kunieda, Kenji [1 ]
Tsushima, Takahiro [1 ]
Yokota, Tomoya [1 ]
Machida, Nozomu [1 ]
Yamazaki, Kentaro [1 ]
Onozawa, Yusuke [2 ]
Yasui, Hirofumi [1 ]
机构：
[1] Shizuoka Canc Ctr, Divisiont Gastrointestinal Oncol, Shizuoka, Japan
[2] Shizuoka Canc Ctr, Div Med Oncol, Shizuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu435.120
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O3-13-3
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer
    Su, Dan
    Jiao, Shun-Chang
    Wang, Li-Jie
    Shi, Wei-Wei
    Long, Yan-Yan
    Li, Juan
    Bai, Li
    TUMOR BIOLOGY, 2014, 35 (03) : 2313 - 2318
  • [2] Clinical benefit with gemcitabine (GEM) as first-line therapy for patients with advanced pancreatic cancer (APC)
    Manzano, H
    Esquerdo, G
    Rifa, J
    Aguiar, D
    Arrivi, A
    Pazo, R
    Martin, J
    Terrasa, J
    ANNALS OF ONCOLOGY, 1998, 9 : 54 - 54
  • [3] Gemcitabine confirmed as the first-line therapy for pancreatic cancer
    Claire Greenhill
    Nature Reviews Gastroenterology & Hepatology, 2011, 8 (1) : 3 - 3
  • [4] Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
    Nagata, Y.
    Kinoshita, C.
    Ishimoto, U.
    Kano, T.
    Ishikawa, M.
    Mikuni, H.
    Nakatsuka, K.
    Harada, K.
    Nishimura, T.
    Noguchi, M.
    Sawada, R.
    Amano, K.
    Saruta, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Safety and efficacy of first-line gemcitabine plus nab-paclitaxel for elderly metastatic pancreatic cancer patients
    Pecora, I.
    Vivaldi, C.
    Rovesti, G.
    Catanese, S.
    Salani, F.
    Gardini, A. Casadei
    Massa, V.
    Bernardini, L.
    Riggi, M.
    Andrikou, K.
    Rapposelli, I.
    Formica, V.
    Cesario, S.
    Caccese, M.
    Lencioni, M.
    Vasile, E.
    Falcone, A.
    Fornaro, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S151 - S151
  • [6] EFFICACY AND SAFETY OF GEMCITABINE PLUS CISPLATIN AS FIRST-LINE CHEMOTHERAPY FOR ADVANCED BILIARY TRACT CANCER
    Oka, Y.
    Todaka, A.
    Fukutomi, A.
    Tsushima, T.
    Yokota, T.
    Machida, N.
    Yamazaki, K.
    Onozawa, Y.
    Boku, N.
    Yasui, H.
    ANNALS OF ONCOLOGY, 2013, 24 : 44 - 44
  • [7] A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
    Steven J. Cohen
    Mark M. Zalupski
    Manuel R. Modiano
    Paul Conkling
    Yehuda Z. Patt
    Peg Davis
    Robert T. Dorr
    Michelle L. Boytim
    Evan M. Hersh
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 287 - 294
  • [8] Gemcitabine Plus Irinotecan as First-Line Weekly Therapy in Locally Advanced and/or Metastatic Pancreatic Cancer
    Neri, B.
    Cipriani, G.
    Grifoni, R.
    Molinara, E.
    Pantaleo, P.
    Rangan, S.
    Vannini, A.
    Tonelli, P.
    Valeri, A.
    Pantalone, D.
    Taddei, A.
    Bechi, P.
    ONCOLOGY RESEARCH, 2009, 17 (11-12) : 559 - 564
  • [9] A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
    Cohen, Steven J.
    Zalupski, Mark M.
    Modiano, Manuel R.
    Conkling, Paul
    Patt, Yehuda Z.
    Davis, Peg
    Dorr, Robert T.
    Boytim, Michelle L.
    Hersh, Evan M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) : 287 - 294
  • [10] Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
    Lim, Jae Yun
    Cho, Jang Ho
    Lee, Se Joon
    Lee, Dong Ki
    Yoon, Dong Sup
    Cho, Jae Yong
    CANCER RESEARCH AND TREATMENT, 2015, 47 (02): : 266 - 273
12345